Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

Oleg Gluz, Sherko Küemmel, Ulrike Nitz, Michael Braun, Kerstin Lüdtke-Heckenkamp, Raquel von Schumann, Maren Darsow, Helmut Forstbauer, Jochem Potenberg, Christoph Uleer, Eva‐Maria Grischke, Bahriye Aktas, Claudia Schumacher, Christine zu Eulenburg, Ronald Kates, Katarzyna Jóźwiak, Monika Graeser, Rachel Wuerstlein, R. Baehner, Matthias Christgen, Hans Kreipe, Nadia Harbeck